Oral Roflumilast Effective, Safe in Treating Plaque Psoriasis Over 24 Weeks


New late-breaking data showed that oral roflumilast treatment was both safe and efficacious against psoriasis, making it a potentially less expensive and convenient treatment alternative.

Treating moderate-to-severe plaque psoriasis with oral roflumilast led to substantial improvements in Psoriasis Area and Severity Index (PASI) scores compared to placebo, according to new data.1

This late-breaking data was presented by Alexander Egeberg, MD, PhD, at the American Academy of Dermatology (AAD) 2023 Annual Meeting in New Orleans, LA. Egeberg is a professor of dermatology at the University of Copenhagen and Bispebjerg Hospital in Denmark.

The drug is a targeted phosphodiesterase (PDE)-4 inhibitor, and PDE-4 is involved in psoriasis pathogenesis. That being said, the Egeberg and colleagues noted that the efficacy and safety of oral roflumilast for those with psoriasis is still unclear.

The investigators conducted a multicenter, randomized, double-blind, placebo-controlled study in which they randomized participants 1 to 1 to be treated with oral roflumilast (500 μg once-per-day) or a placebo.

The placebo arm of the study was switched to being treated with roflumilast at 12 weeks through to week 24. The investigators determined their primary endpoint would be a 75% or greater PASI score reduction from baseline at 12 weeks.

The investigators ended up randomizing 46 total participants, finding that by 12 weeks 34.8% of treatment group participants were able to reach PASI75 compared to 0.0% of the placebo group. They also found 65.2% had PASI50, 43.5% had PASI75, 21.7% had PASI90, and 8.7% of patients had PASI100 responses at 24 weeks.

The investigators also noted that the most common adverse events reported in both arms of the study were weight-loss, headaches, transient gastrointestinal symptoms, and insomnia.

The investigators also concluded that, given this data, roflumilast may end up becoming a cheaper alternative therapy to other psoriasis drugs.


  1. Efficacy and safety of oral roflumilast in the treatment of moderate-to-severe psoriasis – a randomized, double-blinded, placebo-controlled trial (PSORRO). Paper presented at: American Academy of Dermatology 2023 Annual Meeting; March 17 – 21. New Orleans, LA. Accessed March 20, 2023.
Related Videos
Why Are Adult ADHD Cases Climbing?
How Psoriatic Arthritis Presentation, Treatment Has Evolved
Optimizing Diabetes Therapies with New Classifications
Anthony Lembo, MD | Credit: Cleveland Clinic
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Elizabeth Aby, MD | Credit: Minnesota Health Fairview
Prashant Singh, MD | Credit: University of Michigan
Noa Krugliak Cleveland, MD | Credit: University of Chicago
Caroline Sisson, MMS, PA-C: Updates in Pulmonary Function Testing
Ali Rezaie, MD | Credit: X
© 2024 MJH Life Sciences

All rights reserved.